Relationship between 666C>T polymorphism of TIMP-1 and lumbar intervertebral disc degeneration

National Medical Journal of China

Volumn 90, Issue 41, 2010, Pages 2939-2942

  Xiao, Bin ^a   Tian, Wei ^a   Zhao, Dan Hui ^b   Wu, Cheng Ai ^b   Wang, Na ^b   Zhang, Yan Zhuo ^b  

^a Beijing Jishuitan Hospital   (China)

^b NONE

Author keywords

Intervertebral disk; Polymorphism, single nucleotide; Tissue inhibitor of metalloproteinase 1

Indexed keywords

GENOMIC DNA; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; ARTICLE; CHINA; CHINESE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; EXON; GENETIC ASSOCIATION; HOMOZYGOTE; HUMAN; INTERVERTEBRAL DISK DEGENERATION; LUMBAR INTERVERTEBRAL DISK DEGENERATION; SINGLE NUCLEOTIDE POLYMORPHISM; ADOLESCENT; GENETICS; GENOTYPE; LUMBAR VERTEBRA; MALE;

ADOLESCENT; ADULT; GENOTYPE; HUMANS; INTERVERTEBRAL DISK DEGENERATION; LUMBAR VERTEBRAE; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; TISSUE INHIBITOR OF METALLOPROTEINASE-1; YOUNG ADULT;

EID: 84871447381     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2010.41.014     Document Type: Article

References (28)

1. Miller J A, Schmatz C, Schultz A B. Lumbar disc degeneration: Correlation with age, sex, and spine level in 600 autopsy specimens. Spine, 1988, 13:173-178.
2. 2007, 87:1940-1943.
3. Anderson D G, Albert T J, Fraser J K, et al. Cellular therapy for disc degeneration. Spine, 2005, 30: S14-S19.
4. Adams M A, Roughley P J. What is intervertebral disc degeneration, and what causes it? Spine, 2006, 31: 2151-2161.
5. Levicoff E A, Gilbertson L G, Kang J D. Gene therapy for disc repair. Spine J, 2005, 5: 287-296.
6. Boyd L M, Chen J, Kraus V B, et al. Conditioned medium differentially regulates matrix protein gene expression in cells of the intervertebral disc. Spine, 2004, 29: 2217-2222.
7. Battie M C, Videman T, Kaprio J, et al. The twin spine study: contributions to a changing view of disc degeneration. Spine J, 2009, 9:47-59.
8. Khokha R, Waterhouse P, Yagel S, et al. Antisense RNA induced reduction in murine TIMP levels confers oncogenicity on Swiss 3T3 cells. Science, 1989, 243:947-950.
9. Lambert E, Dassé E, Haye B, et al. TIMPs as multifacial proteins. Crit Rev Oncol Hematol, 2004, 49:187-198.
10. Tuuttila A, Morgunova E, Bergmann U, et al. Three-dimensional structure of human tissue inhibitor of metalloproteinases-2 at 2.1 A resolution. J Mol Biol, 1998, 284:1133-1140.
11. Valdes A M, Hassett G, Hart D J, et al. Radiographic progression of lumbar spine disc degeneration is influenced by variation at inflammatory genes: a candidate SNP association study in the chingford cohort. Spine, 2005, 30:2445-2451.
12. Pfirrmann C W, Metzdorf A, Zanetti M, et al. Magnetic resonance classification of lumbar intervertebral disc degeneration. Spine, 2001, 26:1873-1878.
13. Yoon S T, Patel N M. Molecular therapy of the intervertebral disc. Eur Spine J, 2006, 15 Suppl 3:S379-S388.
14. Rosenberg G A. Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol, 2009, 8: 205-216.
15. Altadill A, Rodriguez M, Gonzalez L O, et al. Liver expression of matrix metalloproteases and their inhibitors in hepatocellular carcinoma. Dig Liver Dis, 2009, 41:740-748.
16. Krane S M, Inada M. Matrix metalloproteinases and bone. Bone, 2008, 43:7-18.
17. Roberts S, Caterson B, Menage J, et al. Matrix metalloproteinases and aggrecanase: their role in disorders of the human intervertebral disc. Spine, 2000, 25: 3005-3013.
18. Bachmeier B E, Nerlich A, Mittermaier N, et al. Matrix metalloproteinase expression levels suggest distinct enzyme roles during lumbar disc herniation and degeneration. Eur Spine J, 2009, 18:1573-1586.
19. Le Maitre C L, Freemont A J, Hoyland J A. Localization of degradative enzymes and their inhibitors in the degenerate human intervertebral disc. J Pathol, 2004, 204:47-54.
20. Wallach C J, Sobajima S, Watanabe Y, et al. Gene transfer of the catabolic inhibitor TIMP-1 increases measured proteoglycans in cells from degenerated human intervertebral discs. Spine, 2003, 28:2331-2337.
21. Murphy G, Willenbrock F. Tissue inhibitors of matrix metalloendopeptidases. Methods Enzymol, 1995, 248:496-510.
22. Krawczak M, Reiss J, Cooper D N. The mutational spectrum of single basepair substitutions in mRNA splice junctions of human genes: causes and consequences. Hum Genet, 1992, 90:41-54.
23. Colapietro P, Gervasini C, Natacci F, et al. NF1 exon 7 skipping and sequence alterations in exonic splice enhancers (ESEs) in a neurofibromatosis patient. Hum Genet, 2003, 113:551-554.
24. Cartegni L, Wang J, Zhu Z, et al. ESEfinder: a web resource to identify exonic splicing enhancers. Nucleic Acids Res, 2003, 31: 3568-3571.
25. Lose F, Thompson P J, Duffy D, et al. A novel tissue inhibitor of metalloproteinase-1 (TIMP-1) polymorphism associated with asthma in Australian women. Thorax, 2005, 60:623-628.
26. Overall C M, Kleifeld O. Tumour microenvironment- opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer, 2006, 6:227-239.
27. Yamada H, Watanabe K, Saito T, et al. Esculetin (dihydroxycoumarin) inhibits the production of matrix metalloproteinases in cartilage explants, and oral administration of its prodrug, CPA-926, suppresses cartilage destruction in rabbit experimental osteoarthritis. J Rheumatol, 1999, 26: 654-662.
28. Hu J, Van den Steen P E, Sang Q X, et al. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov, 2007, 6:480-498.